EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development

Sree Karani Kondapuram, Hema Kasthuri Ramachandran, Hemant Arya, Mohane Selvaraj Coumar

Life Sciences · 2023-12 · 335 · 122260

DOI: 10.1016/j.lfs.2023.122260 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life Sciences, 2023-12. Verfasst von Sree Karani Kondapuram und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India. Hauptthemen laut MEDLINE: Neoplasms, Vaccines. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 161 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Survivin is a member of the family of inhibitors of apoptosis proteins (IAPs). It is involved in the normal mitotic process and acts as an anti-apoptotic molecule. While terminally differentiated normal tissues lack survivin, several human malignancies have significant protein levels. Resistance to chemotherapy and radiation in tumor cells is associated with survivin expression. Decreased tumor development, apoptosis, and increased sensitivity to chemotherapy and radiation are all effects of downregulating survivin expression or activity. As a prospective cancer treatment, small molecules targeting the transcription and translation of survivin and molecules that can directly bind with the survivin are being explored both in pre-clinical and clinics. Pre-clinical investigations have found and demonstrated the effectiveness of several small-molecule survivin inhibitors. Unfortunately, these inhibitors have also been shown to have off-target effects, which could limit their clinical utility. In addition to small molecules, several survivin peptide vaccines are currently under development. These vaccines are designed to elicit a cytotoxic T-cell response against survivin, which could lead to the destruction of tumor cells expressing survivin. Some survivin-based vaccines are advancing through Phase II clinical studies. Overall, survivin is a promising cancer drug target. However, challenges still need to be addressed before the survivin targeted therapies can be widely used in the clinics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsVaccinesHumansSurvivinInhibitor of Apoptosis ProteinsApoptosisMicrotubule-Associated Proteins

Stichwörter der Autor:innen

BIRC5Cancer therapyDrug resistanceInhibitor of apoptosisSurvivinVaccine

Substanzen

SurvivinInhibitor of Apoptosis ProteinsVaccinesMicrotubule-Associated Proteins

Autor:innen und Institutionen

  • Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India.
  • Institute for Biochemistry and Pathobiochemistry, Department of Systems Biochemistry, Faculty of Medicine, Ruhr University Bochum, 44780 Bochum, Germany.
  • Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India. Electronic address: mohane@bicpu.edu.in.

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Indian Council of Medical Research

Zitieren

APA

Kondapuram, S. K., Ramachandran, H. K., Arya, H., & Coumar, M. S. (2023). Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development. Life Sciences, 335, 122260. https://doi.org/10.1016/j.lfs.2023.122260

Vancouver

Kondapuram SK, Ramachandran HK, Arya H, Coumar MS. Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development. Life Sciences. 2023;335:122260. doi:10.1016/j.lfs.2023.122260

BibTeX
@article{Kondapuram2023,
  author = {Kondapuram, Sree Karani and Ramachandran, Hema Kasthuri and Arya, Hemant and Coumar, Mohane Selvaraj},
  title = {Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development},
  journal = {Life Sciences},
  year = {2023},
  volume = {335},
  pages = {122260},
  doi = {10.1016/j.lfs.2023.122260}
}
Kostenlos starten →